Skip to content

Prepectoral and Subpectoral Implant-based Breast Reconstruction

A Multicentric, Open-labeled, Prospective, Randomized Controlled Study to Compare the Satisfaction and Safety of the Prepectoral and Subpectoral Implant-based Breast Reconstruction in Patients Receiving Immediate Breast Reconstruction Using Implant Combined With TiLoop® Bra After Skin Sparing or Nipple-areola Sparing Mastectomy

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04688697
Enrollment
300
Registered
2020-12-30
Start date
2021-05-12
Completion date
2025-12-31
Last updated
2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Carcinoma, Breast Reconstruction

Keywords

breast carcinoma, breast reconstruction, Prepectoral prosthetic breast reconstruction, Complication

Brief summary

Breast cancer is one of the main malignant tumors threatening women's lives. In recent years, the increasing demand for reconstruction of breast cancer patients in China has made the proportion of breast reconstruction increase year by year, while implant reconstruction has become the most important way of breast reconstruction due to its less injury, shorter time of operation and relatively simple surgical technique. In the long-term clinical practice, due to the lack of safe and effective alternative methods, the reconstruction method with prosthesis placed to posterior pectoralis major has been accepted by surgeons and patients, and has become the most commonly used method of prosthesis construction. However, the development of biomaterials provides new ideas for breast reconstruction. At present, more and more doctors in clinical practice discontinue the use of serratus anterior, but use the synthetic mesh (mostly titanium mesh TiLoop® Bra) or allogeneic acellular dermal matrix mesh to cover part of the dilator or prosthesis so as to shorten the entire operation cycle and make the appearance of the reconstructed breast more natural and aesthetic. In particular, it can improve the contour of the folds under the breast and shape the breasts with a certain degree of sagging. This study takes the patients receiving immediate reconstruction with an implant combined with TiLoop® Bra after total mastectomy as the subjects, aiming to compare the aesthetics and safety of the placement of implant to anterior and posterior pectoralis major through a prospective and randomized study. The primary objective of the study is to analyze the aesthetics of breast appearance, patient satisfaction and postoperative quality of life (QOL) of the placement of implant to anterior and posterior pectoralis major. The secondary objective of the study is to analyze the incidence of complications and type of reoperation in both groups.

Interventions

PROCEDUREprepectoral implant-based reconstruction

In this group, patients receive breast reconstruction with prosthesis placed to anterior pectoralis major, synthetic mesh is used to enclose the prosthesis and place it to anterior pectoralis major.

PROCEDUREsubpectoral implant-based reconstruction

In this group, patients receive breast reconstruction with placed to posterior pectoralis major, part of the mesh is placed under the pectoralis major during the operation, and the mesh is used to cover the suture of the prosthesis on the inferior plica, or to directly enclose the lower part of the implant.

Sponsors

Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. More than 18 years old 2. Female 3. Preoperative pathology confirming invasive breast carcinoma or ductal carcinoma in situ 4. Clinical T1 and T2 (Maximum tumor diameter ≤5 cm) 5. Clinical ALN negative (Clinical physical examination and ultrasound indicate axillary lymph node negative; Suspected abnormality of axillary lymph node, and fine needle aspiration negative) 6. No clinical or imaging evidence of distant metastasis 7. Patients to receive skin sparing mastectomy or nipple sparing mastectomy 8. BMI \< 35 9. Patients with no or mild mastoptosis 10. Prosthesis to be implanted \<500 ml 11. Be able and willing to sign the Informed Consent Form (ICF)

Exclusion criteria

1. Patients with the breast of moderate-severe mastoptosis, or requiring the use of Wise-pattern or other breast lift methods for subcutaneous mammary gland resection 2. BMI\>=35 3. Patients who have received symmetrical breast surgery on the unaffected side immediately or later 4. Patients with locally advanced breast cancer to receive neoadjuvant therapy 5. Patients currently participating in other clinical trials, which may have impact on the participation in this trial 6. Neoadjuvant therapy has been completed, and there is clear indication of adjuvant radiotherapy after the operation 7. Previous history of breast cancer (patients with ipsilateral recurrence after breast sparing surgery) 8. Pregnancy breast-feeding women 9. History of smoking 10. Previous history of diabetes

Design outcomes

Primary

MeasureTime frameDescription
Patients' satisfaction18 months after the operationPatients' satisfaction evaluated based on Breast-Q scale

Secondary

MeasureTime frameDescription
Incidences of complications and serious complicationsDuring 18 months after the operationIncidences of complications and serious complications

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026